MK-0524A clinical trials
Also written MK-0524A.
How each study uses MK-0524A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MK-0524A
- 6
Studies by the year they started
6 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses MK-0524A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- MK-0524B Lipid Study (MK-0524B-063)CompletedPhase 3Merck Sharp & Dohme LLCNCT00479882Written as MK-0524A
- Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)CompletedPhase 3Merck Sharp & Dohme LLCNCT00289900Written as MK-0524A
- A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)TerminatedPhase 3Merck Sharp & Dohme LLCNCT01294683Written as Extended Release (ER) niacin/laropiprant (N/LRPT)
- Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00376584Written as MK-0524A
- A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01583647Written as MK-0524A
- MK0524B Bioequivalence Study (0524B-070)CompletedPhase 1Merck Sharp & Dohme LLCNCT00943124Written as MK0524A (ER niacin + laropiprant)